Author | Jill Wechsler

Jill Wechsler is ACT's Washington Editor


Debate Accelerates Over Who Gets COVID Vaccine First


As biopharma companies and research institutes advance the development of promising vaccines against COVID-19, policy makers and health officials have intensified deliberations on strategies for ensuring fair and equitable distribution of anticipated preventives.

Do Biosimilars Require Clinical Trials?

Pharmaceutical Executive


Experts are proposing more limited clinical trials for follow-on therapies in some situations, particularly for critical oncology drugs and for highly targeted treatments for rare conditions. Jill Wechsler reports.